Last updated on Tuesday, 31 January 2017

Christus St Vincent Regional Cancer Center

Trial #TypeStudy StatusStatus DateTitle
SWOG S1207Breast AdjuvantOpen Active2016-03-09SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-11-03ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
ECOG E2112Breast AdvancedOpen Active2016-03-10ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-11-03SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
SWOG S1216GU Prostate AdvancedOpen Active2013-08-01SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
ECOG E1412Hematology Lymphoma Non-HodgkinsOpen Active2016-11-14ECOG E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-12-19ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-12-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-12-09Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST
SWOG S1403Lung NSCLC AdvancedOpen Active2016-12-09SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
UNM 1523SupportiveOpen Active2016-09-21INST UNM 1523: Implementing an Evidence-Based Oral Care Protocol in Head and Neck Patients Receiving Radiation Therapy
Alliance A011401SupportiveOpen Active2016-09-29Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

GI Hepatic Advanced

Trial #TypeStudy StatusStatus DateTitle
COG ALTE03N1PediatricOpen Active2004-07-09COG ALTE03N1: Key Adverse Events After Childhood Cancer
COG AHOD1331PediatricOpen Active2015-05-29COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
COG LTFPediatricOpen Active2003-01-07COG LTF: A Groupwide Procedure for Collecting Long Term Follow Up Data
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2016-04-12ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2016-03-10ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
Pharm NLG-2103Skin Melanoma AdvancedOpen Active2016-09-13NewLink Genetics NLG-2103: A Phase 1/2 Study of the Concomitant Administration of Indoximod plus Ipilimumab for Adult Patients with Metastatic Melanoma
SWOG S1404Skin Melanoma AdvancedOpen Active2016-01-22SWOG S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475
(PEMBROLIZUMAB) in Patients with High Risk Resected Melanoma
Pharm BXQ-350.AASolid Tumors OtherOpen Active2016-11-30Bexion BXQ-350.AA: Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas
COG AREN03B2PediatricOpen Active2006-05-18COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study
Pharm 8273-CL-0302Lung NSCLC AdvancedOpen Active2016-11-03Astellas Pharma 8273-CL-0302: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study)
Pharm TRX518-003Solid Tumors OtherOpen Active2016-09-28Leap Therapeutics. Inc TRX518-003: A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
Pharm 0761-014Solid Tumors OtherOpen Active2016-09-20Kyowa Hakko Kirin 0761-014: Open-label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors
Pharm MK-3475 PN158Solid Tumors OtherOpen Active2016-07-21Merck MK3475 PN158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Pharm 2455-001Solid Tumors OtherOpen Active2016-09-21Kyowa Kirin Pharmaceutical 2455-001: Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in
Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
UNM 1520SupportiveOpen Active2016-04-05INST UNM 1520: Replacing Sedentary Time with Light Activity
ECOG-ACRIN E1Q11SupportiveOpen Active2016-07-15ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
COG ALTE11C2SupportiveOpen Active2014-03-13COG ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
COG ALTE11C1SupportiveOpen Active2014-03-13COG ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
Alliance A011401SupportiveOpen Active2016-10-02Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
GOG 0225SupportiveOpen Active2016-11-10GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
INST 1211SupportiveOpen Active2016-05-24INST 1211: A Pilot Randomized Placebo-Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
Pharm I3Y-MC-JPBJLung NSCLC AdvancedOpen Active2014-08-25Eli Lilly I3Y-MC-JPBJ: A Phase 1b Study of LY2835219 in Combination with Multiple Single-Agent Options for Patients with Stage IV NSCLC
SWOG S1403Lung NSCLC AdvancedOpen Active2016-05-17SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
Pharm 265-109Lung NSCLC AdvancedOpen Active2016-02-10Mirati Therapeutics 265-109: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
SWOG S1400Lung OtherOpen Active2016-03-16SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
NRG Oncology NRG-CC003Lung SCLC AdjuvantOpen Active2016-08-17NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
CALGB 30610Lung SCLC AdjuvantOpen Active2013-10-29CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Pharm G1T28-02Lung SCLC AdvancedOpen Active2016-07-12G1 Therapeutics G1T28-02: Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy
COG ACNS02B3PediatricOpen Active2010-12-06COG ACNS02B3: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
COG ALTE05N1PediatricOpen Active2008-07-21COG ALTE05N1: Umbrella Long-Term Follow-Up Protocol
COG ALTE07C1PediatricOpen Active2009-02-03COG ALTE07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Alliance A091202Sarcoma AdvancedOpen Active2016-10-01Alliance A091202: A Phase II, Randomized, Double Blinded Study Of The Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone Vs. Placebo In Patients With Previously Treated, Unresectable Myxoid Liposarcoma
COG D9902Sarcoma AncillaryOpen Active2001-06-20COG D9902: A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
COG AOST06B1Sarcoma AncillaryOpen Active2008-04-10COG AOST06B1: A Childrens Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
Pharm TLPLDCSkin Melanoma AdvancedOpen Active2016-01-11Cancer Insight TLPLDC: A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (resected) Melanoma to Prevent Recurrence
COG AALL1131Hematology Acute LeukemiaOpen Active2012-03-01COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
COG ACCL0934Hematology Acute LeukemiaOpen Active2011-12-12COG ACCL0934: A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation
COG AAML1031Hematology Acute LeukemiaOpen Active2016-04-11COG AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
COG ACCL1033Hematology Acute LeukemiaOpen Active2012-11-13COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
COG AALL0932Hematology Acute LeukemiaOpen Active2010-10-16COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
COG AALL08B1Hematology Acute LeukemiaOpen Active2010-10-15COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
SWOG S0919Hematology Acute LeukemiaOpen Active2015-08-12SWOG S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia
UNM 1503Hematology Acute LeukemiaOpen Active2016-07-28INST UNM 1503: Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
SWOG S1318Hematology Acute LeukemiaOpen Active2016-04-21SWOG S1318: A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients
COG AALL06N1Hematology Acute LeukemiaOpen Active2009-01-06COG AALL06N1: A Study of Neurocognitive Function in Children Treated for ALL: (A Groupwide, Non-therapeutic Companion Study to AALL0232 and AALL0434)
COG AALL05B1Hematology Acute LeukemiaOpen Active2006-12-12COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
HRRC #03-183Hematology Acute LeukemiaOpen Active2008-01-22HRRC #03-183: Biological Correlates with T-ALL Gene Expression and Clinical Outcome
COG AAML08B1Hematology Acute LeukemiaOpen Active2009-06-08COG AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
Pharm STML-401-0314Hematology Chronic LeukemiaOpen Active2016-04-21Stemline Therapeutics STML-401-0314: SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms
Pharm IPH2201Hematology Chronic LeukemiaOpen Active2016-05-17Innate IPH2201: Open Label Ib/IIa Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or previously untreated Chronic Lymphocytic Leukemia
COG AHOD04B1Hematology Lymphoma HodgkinsOpen Active2006-12-12COG AHOD04B1: Hodgkin Disease (HD) Banking Study
Pharm GO29365Hematology Lymphoma Non-HodgkinsOpen Active2016-02-29Genentech GO29365: A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCD S4501A) in Combination with Rituximab (R) or Obinutuxumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
COG AALL1231Hematology Lymphoma Non-HodgkinsOpen Active2015-02-17COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
COG ANHL12P1Hematology Lymphoma Non-HodgkinsOpen Active2014-03-13COG ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
ECOG E1412Hematology Lymphoma Non-HodgkinsOpen Active2016-10-04ECOG E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
ECOG-ACRIN NHLBI-MDSHematology MyelomaOpen Active2016-10-06ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
ECOG-ACRIN E1A11Hematology MyelomaOpen Active2016-06-26ECOG ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
ECOG E3A06Hematology MyelomaOpen Active2016-07-20ECOG E3A06: Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Pharm SGN33A-004Hematology OtherOpen Active2016-05-17Seattle Genetics SGN33A-004: A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High-risk Myelodysplastic Syndrome (MDS)
INST H-25667Hematology OtherOpen Active2012-08-25INST H-25667: The Molecular Basis of Histiocytic Diseases
Pharm 04-30Hematology OtherOpen Active2016-04-14cian
COG ACCRN07Ill DefinedOpen Active2008-02-12COG ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
INST 1101Ill DefinedOpen Active2011-03-30INST 1101: Investigating Cancer-Related Information Processing of Patients and Family Members
COG ANBL0032Ill DefinedOpen Active2009-04-30COG ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
COG ANBL00B1Ill DefinedOpen Active2001-07-11COG ANBL00B1: Neuroblastoma Biology Study
UNM 1522Ill DefinedOpen Active2015-10-29INST UNM 1522: A Community-Engaged Approach to Understanding Health Related Quality of Life and Care Management Issues Among Cancer Survivors and Their Caregivers
Pharm Eli Lilly I3Y-MC-JPBOIll DefinedOpen Active2016-07-01Eli Lilly I3Y-MC-JPBO: A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
NCI 9671Ill DefinedOpen Active2015-07-06NCI 9671: Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders
Pharm 516-001Ill DefinedOpen Active2016-02-05Mirati, Inc. 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
INST 1306Ill DefinedOpen Active2015-01-01INST 1306: Whole Genome Sequencing of Human Cancer Tissues
COG ABTR01B1Ill DefinedOpen Active2010-12-01COG ABTR01B1: A Childrens Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
COG ANBL1221Ill DefinedOpen Active2016-08-01COG ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
INST DFCI 09-250Ill DefinedOpen Active2013-05-01INST DFCI 09-250: Coping with Cancer II
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-05-09ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2016-12-05ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
RTOG 1306Lung NSCLC AdvancedOpen Active2015-12-18RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Pharm D419AC00003Lung NSCLC AdvancedOpen Active2016-01-28AstraZeneca D419AC00003: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)(NEPTUNE)
SWOG S1417CDGI OtherOpen Active2016-12-14SWOG S1417CD: Implementation of a Prospective Financial Impact Assessment Tool
in Patients with Metastatic Colorectal Cancer
COG 9442GU OtherOpen Active1997-12-12COG 9442: National Wilms Tumor Late Effect Study
SWOG S1500GU OtherOpen Active2016-07-07SWOG S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC#749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
NRG Oncology NRG-GU001GU OtherOpen Active2016-07-05NRG Oncology NRG-GU001: Randomized Phase 2 Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer
Pharm PrTK03GU Prostate AdjuvantOpen Active2015-07-07Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
SWOG S1216GU Prostate AdvancedOpen Active2013-07-30SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
Pharm INO-VT-464-CL-003GU Prostate AdvancedOpen Active2016-10-04Innocrin Pharmaceuticals INO-VT-464-CL-003: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Pharm RX-0201-P2-A-09GU Renal Cell AdvancedOpen Active2016-08-03Rexahn RX-0201-P2-A-09: A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma
Pharm A041-04GU Renal Cell AdvancedOpen Active2015-05-06Acceleron A041-04: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Pharm GU14-182GU Ureter AdvancedOpen Active2016-09-28Hoosier Cancer Research Network GU14-182: A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-07-23RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-10-20GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG 0274GYN Cervical AdvancedOpen Active2012-06-28GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
Pharm M13-694 - GOG-3005GYN OtherOpen Active2016-12-12AbbVie M13-694/GOG-3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
UNM 1509GYN OtherOpen Active2015-12-02INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG Oncology NRG-GY005GYN OtherOpen Active2016-05-09NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2016-05-10NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
GOG-0281GYN Ovarian AdjuvantOpen Active2016-10-05GOG-0281: A Randomized Phase II/III Study To Assess The Efficacy Of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer
UNM 1419GYN Ovarian AdvancedOpen Active2016-05-31INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Pharm CL-PTL-119GYN Ovarian AdvancedOpen Active2016-01-12Gradalis CL-PTL-119: Double-Blind, Placebo Controlled Phase III Trial of Maintenance FANG (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer
GOG 0213GYN Ovarian AdvancedOpen Active2008-02-26GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
INST CR1204GYN Ovarian AdvancedOpen Active2012-12-21INST CR1204: Pilot Study of Ketorolac and Ovarian Cancer Survival
Pharm B9991009/GOG 3013GYN Ovarian AdvancedOpen Active2016-09-28Pfizer B9991009/GOG 3013: A Phase 3, Multicenter, Randomized, Open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with Platinum-Resistant/Refractory Ovarian Cancer
INST 1420GYN Ovarian NeoadjuvantOpen Active2015-10-29INST 1420: A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-12-14ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ECOG E3311Head And Neck AdvancedOpen Active2016-04-05ECOG E3311: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
INST 1008Head And Neck AdvancedOpen Active2014-12-11INST 1008: Expression and Epigenetic Silencing of MicroRNA for Predicting the Therapeutic Response and Prognosis of HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
RTOG 0920Head And Neck AdvancedOpen Active2010-07-13RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
NRG Oncology NRG-HN002Head And Neck AdvancedOpen Active2016-01-27NRG Oncology NRG-HN002: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Pharm MK-3475-048-00Head And Neck AdvancedOpen Active2016-05-03Merck MK-3475-048-00: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma

Lovelace Cancer Care

Trial #TypeStudy StatusStatus DateTitle
SWOG S1207Breast AdjuvantOpen Active2015-06-09SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-08-01ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
NSABP B-55/BIG 6-13Breast AdjuvantOpen Active2016-09-20NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
SWOG S1416Breast AdvancedOpen Active2016-09-26SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
SWOG S1216GU Prostate AdvancedOpen Active2015-06-09SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
INST 96144Ill DefinedOpen Active2015-07-28INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-05-12ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG S1403Lung NSCLC AdvancedOpen Active2016-06-02SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
SWOG S1400Lung OtherOpen Active2016-05-03SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-12ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Alliance A011401SupportiveOpen Active2016-09-17Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
Alliance A011202Breast AdjuvantOpen Active2016-08-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2016-12-16ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
SWOG S1403Lung NSCLC AdvancedOpen Active2016-04-09SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
Pharm 8273-CL-0302Lung NSCLC AdvancedOpen Active2016-11-16Astellas Pharma 8273-CL-0302: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study)
SWOG S1400Lung OtherOpen Active2016-03-16SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2016-04-12ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN E1Q11SupportiveOpen Active2016-12-19ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
Alliance A011401SupportiveOpen Active2016-12-16Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
SWOG S1207Breast AdjuvantOpen Active2013-11-01SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
RTOG 1119Breast AdvancedOpen Active2016-10-06RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-12-16SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
ECOG E2112Breast AdvancedOpen Active2014-09-03ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
SWOG S1216GU Prostate AdvancedOpen Active2013-07-30SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
RTOG 0924GU Prostate AdvancedOpen Active2015-08-04RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
GOG 0263GYN Cervical AdjuvantOpen Active2011-02-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG 0274GYN Cervical AdvancedOpen Active2016-02-26GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
NRG Oncology NRG-GY005GYN OtherOpen Active2016-09-09NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2016-09-07NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
GOG 0213GYN Ovarian AdvancedOpen Active2010-06-25GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
ECOG E1412Hematology Lymphoma Non-HodgkinsOpen Active2016-10-04ECOG E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
ECOG-ACRIN E1A11Hematology MyelomaOpen Active2016-11-07ECOG ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
NCI 9671Ill DefinedOpen Active2015-07-21NCI 9671: Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-04-21ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
NSABP B-51Breast AdjuvantOpen Active2016-10-20NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1207Breast AdjuvantOpen Active2015-04-14SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-08-30SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
ECOG E2112Breast AdvancedOpen Active2015-04-20ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
NRG Oncology NRG-GU001GU OtherOpen Active2016-08-22NRG Oncology NRG-GU001: Randomized Phase 2 Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer
Pharm PrTK03GU Prostate AdjuvantOpen Active2016-02-23Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-10-26ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
INST 96144Ill DefinedOpen Active2014-12-09INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-05-17ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST
RTOG 1306Lung NSCLC AdvancedOpen Active2015-12-18RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
SWOG S1403Lung NSCLC AdvancedOpen Active2016-05-25SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
SWOG S1400Lung OtherOpen Active2016-03-16SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2016-04-12ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2016-04-13ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
INST 1211SupportiveOpen Active2016-05-24INST 1211: A Pilot Randomized Placebo-Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
INST 2014-0443Breast AdjuvantOpen Active2015-04-02MD Anderson Cancer Center 2014-0443: Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
SWOG S1207Breast AdjuvantOpen Active2013-04-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Pharm A041-04GU Renal Cell AdvancedOpen Active2015-08-03Acceleron A041-04: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma
ECOG E1412Hematology Lymphoma Non-HodgkinsOpen Active2016-10-04ECOG E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
INST 96144Ill DefinedOpen Active2013-06-04INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-04-21ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Pharm 8273-CL-0302Lung NSCLC AdvancedOpen Active2016-11-16Astellas Pharma 8273-CL-0302: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study)
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2016-03-16ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2016-04-12ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Alliance A011401SupportiveOpen Active2016-11-01Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-07-06ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2016-07-06ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY002GYN Cervical AdvancedOpen Active2016-05-03NRG Oncology NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
GOG 0274GYN Cervical AdvancedOpen Active2012-07-30GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
NRG Oncology NRG-GY005GYN OtherOpen Active2016-05-19NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Pharm M13-694 - GOG-3005GYN OtherOpen Active2016-12-12AbbVie M13-694/GOG-3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-0281GYN Ovarian AdjuvantOpen Active2016-10-05GOG-0281: A Randomized Phase II/III Study To Assess The Efficacy Of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2016-05-20NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG 0213GYN Ovarian AdvancedOpen Active2009-09-01GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG 0277GYN Uterine AdvancedOpen Active2013-04-16GOG 0277: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC#
628503) Followed BY Doxorubicin (NSC# 123127) versus Observation for Uterus-limited,
High-grade Uterine Leiomyosarcoma
SWOG S1404Skin Melanoma AdvancedOpen Active2016-03-23SWOG S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475
(PEMBROLIZUMAB) in Patients with High Risk Resected Melanoma
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
GOG 0225SupportiveOpen Active2016-11-10GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alliance A221405, IBCSG 48-14, BIG 8-13Breast OtherOpen Active2016-10-13Alliance A221405, IBCSG 48-14, BIG 8-13: POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer
INST 0818Breast OtherOpen Active2016-01-29INST 0818: High-Speed MR Spectroscopic Imaging of Choline and Lipids in Breast Cancer
UNM 1525Breast PreventionOpen Active2016-09-22INST UNM 1525: Breast cancer screening among medically underserved women in New Mexico: Comparing outcomes and LOwering recall rates with digital breast tomosynthesis (3D mammography) VErsus full-field digital (2D) mammography. The LOVE New Mexico study)
UNM 1528EpidemiologicalOpen Active2016-04-01INST UNM 1528: Improving Colorectal Cancer Screening Rates in New Mexico Hispanics through Community Partnerships and Implementation Science
UNM 1602EpidemiologicalOpen Active2016-07-01INST UNM 1602: Genetic Risk Assessment for Education and Empowerment (GRACE): Intervention Pilot Study
COG AEWS07B1EpidemiologicalOpen Active2008-03-21COG AEWS07B1: A COG Study for Collecting and Banking Ewing Sarcoma Specimens
UNM 1519EpidemiologicalOpen Active2016-08-26INST UNM 1519: Pilot Study for a Cancer Epidemiology Cohort of Ovarian, Endometrial, Bladder and Kidney Cancer Patients
NCCTG N1048GI Colorectal AdvancedOpen Active2013-02-13NCCTG N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
INST 1204GI Colorectal AncillaryOpen Active2012-05-22INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer
COG AHEP0731GI Hepatic AdjuvantOpen Active2010-01-13COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma
SCUSF 0901Brain AdjuvantOpen Active2012-05-02SCUSF 0901 [COG ACCL0922] A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
COG ACNS0831Brain AdjuvantOpen Active2010-12-02COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
COG ACNS0332Brain AdjuvantOpen Active2015-06-22COG ACNS0332: A Groupwide Phase III Study: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
COG ACNS1123Brain AdjuvantOpen Active2012-08-15COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized
Central Nervous System Germ Cell Tumors (CNS GCT)
NCCTG N0577Brain AdvancedOpen Active2015-08-31NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
INST 1409Brain AdvancedOpen Active2016-03-09INST 1409: Single Center, Phase II Study of Whole Brain Radiation Using IMRT to Spare the Hippocampus while Delivering Differential Doses to Subclinical Sites versus Gross Disease for Treatment of Patients with Brain Metastases
Alliance A071401Brain AdvancedOpen Active2016-07-28Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
Pharm NLG2102Brain AdvancedOpen Active2016-07-13NewLink Genetics Corporation NLG2102: A Phase 1/2 Study of the Combination of Indoximod and Temozolomide for Adult Patients with Temozolomide Refractory Primary Malignant Brain Tumor
Pharm C0591001Brain AdvancedOpen Active2016-11-08Pfizer C0591001: A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Gliomas
NSABP B-55/BIG 6-13Breast AdjuvantOpen Active2015-01-20NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-08-01NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
INST 2014-0443Breast AdjuvantOpen Active2015-07-13MD Anderson Cancer Center 2014-0443: Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Alliance A011202Breast AdjuvantOpen Active2016-03-02Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-16ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1207Breast AdjuvantOpen Active2013-03-26SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
RTOG 1119Breast AdvancedOpen Active2016-10-06RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer
NRG-BR002Breast AdvancedOpen Active2016-04-07NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
ECOG E2112Breast AdvancedOpen Active2014-06-03ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-09-26SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011203Breast AdvancedOpen Active2015-12-18Alliance A011203: A Randomized Phase II Trial of Tamoxifen versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

UNM - Lovelace

Trial #TypeStudy StatusStatus DateTitle
05/01/2017Lung NSCLC Adjuvant1969-12-31Page -1 of 1
Total Studies:Lung NSCLC Adjuvant1969-12-31163
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2016-12-05ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)